SCHEMBL10043840

SCHEMBL10043840

COc1ccc(CNC(=O)Nc2ccc(C)c(-c3cc4cnc(C)cc4n(C)c3=O)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 2/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
POLB P06746 1/20 0.47
FGFR1 P11362 1/20 0.45
SRC P12931 1/20 0.45
MCHR1 Q99705 1/20 0.44
MAPK1 P28482 1/20 0.44
ROCK2 O75116 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
RPS6KB1 P23443 1/20 0.42
CDK2 P24941 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL501986 0.92 NPC1 (0.47) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL10043825 0.90 FGFR1 (0.48) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL10043842 0.90 RAB9A (0.48) MEN1KMT2AHTTMAPTNPC1
SCHEMBL10043836 0.90 MAPT (0.46) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL10043826 0.90 MAPK1 (0.45) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL10043843 0.86 MEN1 (0.53) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL502302 0.85 FGFR1 (0.44) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL10043667 0.85 MEN1 (0.47) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL10043833 0.84 RAB9A (0.46) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL10043827 0.84 MAPT (0.53) MEN1KMT2AHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MEN1 4240/4885KMT2A 1257/4885HTT 3065/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MEN1 4240/4885KMT2A 1257/4885HTT 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.